TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,729 | -92.6% | 529 | -87.3% | 0.00% | – |
| Q2 2023 | $64,220 | +112566.7% | 4,181 | +65.6% | 0.00% | – |
| Q1 2023 | $57 | +7.5% | 2,524 | +1.0% | 0.00% | – |
| Q4 2022 | $53 | -99.9% | 2,500 | -1.9% | 0.00% | -100.0% |
| Q3 2022 | $63,000 | +3.3% | 2,549 | +2.0% | 0.00% | 0.0% |
| Q2 2022 | $61,000 | -49.2% | 2,500 | -46.5% | 0.00% | 0.0% |
| Q1 2022 | $120,000 | -10.4% | 4,670 | -3.9% | 0.00% | 0.0% |
| Q4 2021 | $134,000 | +71.8% | 4,860 | +50.9% | 0.00% | – |
| Q3 2021 | $78,000 | +143.8% | 3,220 | +45.0% | 0.00% | – |
| Q2 2021 | $32,000 | -83.2% | 2,220 | -70.9% | 0.00% | -100.0% |
| Q1 2021 | $190,000 | -8.7% | 7,620 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $208,000 | – | 7,620 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |